Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2003

01-05-2003 | Concise Article

Two Cases of Cerebral Aspergillosis Successfully Treated with Voriconazole

Authors: V. de Lastours, A. Lefort, M. Zappa, V. Dufour, N. Belmatoug, B. Fantin

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2003

Login to get access

Abstract

Described here are two cases of cerebral aspergillosis successfully treated with voriconazole after the failure of first-line treatment with amphotericin B deoxycholate. In both cases, clinical and radiological cure was achieved within 6 weeks. Voriconazole should be considered as first-line therapy for cerebral aspergillosis.
Literature
1.
Walsh TJ, Hier DB, Caplan LR (1985) Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol 18:574–582
2.
Torre-Cisneros J, Lopez OL, Kusne S, Martinez AJ, Starzl TE, Simmons RL, Martin M (1993) Aspergillosis in organ transplantation: a clinicopathological study. J Neurol Neurosurg Psychiatry 56:188–193PubMed
3.
Boes B, Bashir R, Boes C, Hahn F, McConnell JR, McComb R (1994) Central nervous system aspergillosis. Analysis of 26 patients. J Neuroimaging 4:123–129PubMed
4.
Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30:696–709PubMed
5.
Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781–805PubMed
6.
Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A (1994) NIAID Mycoses Study Group Multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135–144
7.
Karim M, Alam M, Shah AA, Ahmed R, Sheikh H (1997) Chronic invasive aspergillosis in apparently immunocompetent hosts. Clin Infect Dis 24:723–733PubMed
8.
Coleman JM, Hogg GG, Rosenfeld JV, Waters KD (1995) Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery: case report and review of the literature. Neurosurgery 36:858–863PubMed
9.
Denning DW, Stevens DA (1990) Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12:1147–1201
10.
Denning DW (1996) Therapeutic outcome of invasive aspergillosis. Clin Infect Dis 23:608–615PubMed
11.
Hoffman HL, Rathbun RC (2002) Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 11:409–429PubMed
12.
Jezequel SG, Clark M, Evans K, Roffey S, Wastall P, Webster R (1995) UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: disposition on animals. In: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. F-77
13.
Denning DW (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:573–571CrossRef
14.
Schwartz S, Milatovic D, Thiel E (1997) Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 97:663–665
15.
Herbrecht R, Denning DW, Patterson TF (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMed
16.
Shellito JE, Quan Zheng M, Ye P, Ruan S, Shean MK, Kolls J (2001) Effect of alcohol consumption on host release of interleukin-17 during pulmonary infection with Klebsiella pneumoniae. Alcohol Clin Exp Res 25:872–881PubMed
17.
Ascah KJ, Hyland RH, Hutcheon MA, Urbanski SJ, Pruzanski W, St Louis EL, Jones DP, Keystone EC (1984) Invasive aspergillosis in a "healthy" patient. Can Med Assoc J 131:332–335PubMed
18.
Lortholary O, Meyohas MC, Dupont B, Cadranel J, Salmon-Ceron D, Peyramond D, Simonin D (1993) Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med 95:177–187PubMed
Metadata
Title
Two Cases of Cerebral Aspergillosis Successfully Treated with Voriconazole
Authors
V. de Lastours
A. Lefort
M. Zappa
V. Dufour
N. Belmatoug
B. Fantin
Publication date
01-05-2003
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2003
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-0934-2

Other articles of this Issue 5/2003

European Journal of Clinical Microbiology & Infectious Diseases 5/2003 Go to the issue

Brief Report

Infantile Diarrhoea Associated with Sorbitol-Fermenting, Non-Shiga Toxin-Producing Escherichia coli O157:H−

Concise Article

Non-Fatal Acute Liver Injury Possibly Related to High-Dose Ciprofloxacin

Brief Report

Shift of the Tick Ixodes ricinus and Tick-Borne Encephalitis to Higher Altitudes in Central Europe

Brief Report

Identification of Staphylococcus Species in Blood Cultures by a Rapid Commercial DNA Probe Test

Article

Triple Faeces Test: An Effective Tool for Detection of Intestinal Parasites in Routine Clinical Practice

Concise Article

Lack of Portosystemic Bacterial Translocation in Patients with Liver Cirrhosis after Placement of Transjugular Shunt
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits